TY - JOUR
T1 - Netherton syndrome with ichthyosis linearis circumflexa and trichorrhexis invaginatum
AU - Ng, Elise
AU - Hale, Christopher S.
AU - Meehan, Shane A.
AU - Cohen, David E.
N1 - Publisher Copyright:
© 2015 by the article author(s).
PY - 2015
Y1 - 2015
N2 - Netherton syndrome is a rare, autosomal recessive disorder that is characterized by congenital ichthyosis, trichorrhexis invaginata, and atopic diathesis. Ichthyosis presents at birth with erythroderma and subsequently evolves into ichthyosis linearis circumflexa; hair shaft abnormalities tend to present later. The disorder is caused by loss-of-function mutations in the SPINK5 (serine protease inhibitor Kazal-type 5) gene that encodes LEKTI (lympho-epithelial Kazal-type related inhibitor), which is a protease inhibitor that counteracts epidermal proteases involved in desquamation. Use of topical medications is limited by potential for systemic absorption and toxicity in the setting of a defective skin barrier. Therapeutic options include topical glucocorticoids and retinoids, oral retinoids, and narrowband ultraviolet B phototherapy. Topical tacrolimus has been shown to be efficacious and may be used safely with careful laboratory monitoring.
AB - Netherton syndrome is a rare, autosomal recessive disorder that is characterized by congenital ichthyosis, trichorrhexis invaginata, and atopic diathesis. Ichthyosis presents at birth with erythroderma and subsequently evolves into ichthyosis linearis circumflexa; hair shaft abnormalities tend to present later. The disorder is caused by loss-of-function mutations in the SPINK5 (serine protease inhibitor Kazal-type 5) gene that encodes LEKTI (lympho-epithelial Kazal-type related inhibitor), which is a protease inhibitor that counteracts epidermal proteases involved in desquamation. Use of topical medications is limited by potential for systemic absorption and toxicity in the setting of a defective skin barrier. Therapeutic options include topical glucocorticoids and retinoids, oral retinoids, and narrowband ultraviolet B phototherapy. Topical tacrolimus has been shown to be efficacious and may be used safely with careful laboratory monitoring.
UR - http://www.scopus.com/inward/record.url?scp=84918530863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84918530863&partnerID=8YFLogxK
M3 - Article
C2 - 25526335
AN - SCOPUS:84918530863
SN - 1087-2108
VL - 20
JO - Dermatology online journal
JF - Dermatology online journal
IS - 12
M1 - 7
ER -